BeOne culls five cancer programs and an autoimmune Phase 2

May 6, 2026 02:22 PM EDT R&DPharma BeOne culls five can­cer pro­grams and an au­toim­mune Phase 2 Kyle LaHucik Biotech Correspondent BeOne Med­i­cines has great­ly ex­pand­ed its pipeline over the years, bring­ing 18 new mol­e­c­u­lar en­ti­ties to the fore across 2024 and 2025. But that al­so … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER